Evidence map›Paper›PMID 39639948›Full record

ArticleIJID regions2024

Immune response to GeneVac-B

Nina Genéviève Mathuola Ouattara, Armel Moumouni Sanou, Delphine Napon-Zongo, Abou Coulibaly, Sylviane Korogho, Abdoulaye Dera, Achille S Nikièma, Eric Kyelem, Nawatou Gansoré, Abdoul Kader Ilboudo and 2 more

Abstract read
In one paragraph

Article in IJID regions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nina Genéviève Mathuola OuattaraLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Armel Moumouni SanouLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Delphine Napon-ZongoDépartement Clinique, Centre "Assaut-Hépatites", Bobo-Dioulasso, Burkina Faso.
Abou CoulibalyLaboratoire de Recherche en Santé Publique et Nutrition (LR-SPN), Bobo-Dioulasso, Burkina Faso.
Sylviane KoroghoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Abdoulaye DeraLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Achille S NikièmaLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Eric KyelemLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso.
Nawatou GansoréDépartement Clinique, Centre "Assaut-Hépatites", Bobo-Dioulasso, Burkina Faso.
Abdoul Kader IlboudoDépartement Méthodologie et Gestion des Données, Centre "Assaut-Hépatites", Bobo-Dioulasso, Burkina Faso.
Jeoffray DiendéréLaboratoire de Recherche en Santé Publique et Nutrition (LR-SPN), Bobo-Dioulasso, Burkina Faso.
Gautier Henri OuédraogoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Ouagadougou, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B Methods: This cross-sectional study included individuals fully vaccinated with GeneVac-B Results: A total of 392 participants were included in the study. The mean age was 35.5 ± 15.3 years. Approximately 56% had been previously exposed to hepatitis B virus. Overall, 380 participants had an anti-HBs titer ≥ 12 mIU/ml indicating a seroprotection rate of 96.9%, and 12 had a titer <12 mIU/ml, a nonresponse rate of 3.1%. Among the nonresponders, 11 (11/12; 91.7%) had high total cholesterol levels (>240 mg/dl), and 8 (8/12; 66.7%) were older than 40 years of age. Conclusions: The results showed an excellent immune response to GeneVac-B

Indexed as

Burkina FasoGeneVac-BⓇHepatitis BImmune responseNonresponse factors

Identifiers

PMID39639948
PMCPMC11618024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.